Characterization of response to radiation mediated gene therapy by means of multimodality imaging

Magnetic Resonance in Medicine

Volumn 62, Issue 2, 2009, Pages 348-356

  Haney, Chad R ^a   Parasca, Adrian D ^a   Fan, Xiaobing ^a   Bell, Rebecca M ^a   Zamora, Marta A ^a   Karczmar, Gregory S ^a   Mauceri, Helena J ^a   Halpern, Howard J ^a   Weichselbaum, Ralph R ^a   Pelizzari, Charles A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

DCE MRI; EPRI; Gene therapy; Hypoxia

Indexed keywords

CELL DEATH; GENE THERAPY; MAMMALS; OXYGENATION; PARAMAGNETIC RESONANCE; TUMORS;

DCE-MRI; DYNAMIC CONTRAST ENHANCED MRI; ELECTRON PARAMAGNETIC RESONANCE IMAGING; EPRI; GENETICALLY MODIFIED; HYPOXIA; MULTI-MODALITY IMAGING; TUMOR NECROSIS FACTOR ALPHA;

MAGNETIC RESONANCE IMAGING;

ADENOVIRUS VECTOR; GADODIAMIDE; OXYGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; ELECTRON SPIN RESONANCE; FEMALE; IRRADIATION; MATHEMATICAL MODEL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; TISSUE OXYGENATION; TISSUE PERFUSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE THERAPY;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; PERFUSION IMAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; SUBTRACTION TECHNIQUE; TREATMENT OUTCOME;

EID: 67749089372     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22008     Document Type: Article

References (38)

1. Marks LB, Spencer DP, Bentel GC, Ray SK, Sherouse GW, Sontag MR, Coleman RE, Jaszczak RJ, Turkington TG, Tapson V. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 1993;26:659-668.
2. Hamilton RJ, Sweeney PJ, Pelizzari CA, Yetkin FZ, Holman BL, Garada B, Weichselbaum RR, Chen GT. Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys 1997;37:181-188.
3. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560.
4. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000;46:619-630.
5. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-648.
6. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
7. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
8. Elas M, Bell R, Hleihel D, Barth ED, McFaul C, Haney CR, Bielanska J, Pustelny K, Ahn KH, Pelizzari CA, Kocherginsky M, Halpern HJ. Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. Int J Radiat Oncol Biol Phys 2008;71:542-549.
9. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Gregoire V, Feron O, Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11(Pt 1):743-750.
10. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Gregoire V, Beghein N, Bouzin C, Feron O, Gallez B. Tumor radiosensitization by anti-inflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 2005;65:7911-7916.
11. Jordan BF, Gregoire V, Demeure RJ, Sonveaux P, Feron O, O'Hara J, Vanhulle VP, Delzenne N, Gallez B. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62:3555-3561.
12. Elas M, Ahn KH, Parasca A, Barth ED, Lee D, Haney C, Halpern HJ. Electron paramagnetic resonance oxygen images correlate spatially and quantitatively with Oxylite oxygen measurements. Clin Cancer Res 2006;12(Pt 1):4209-4217.
13. Elas M, Williams BB, Parasca A, Mailer C, Pelizzari CA, Lewis MA, River JN, Karczmar GS, Barth ED, Halpern HJ. Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn Reson Med 2003;49:682-691.
14. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002;9: 951-957.
15. Chung TD, Mauceri HJ, Hallahan DE, Yu JJ, Chung S, Grdina WL, Yajnik S, Kufe DW, Weichselbaum RR. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther 1998;5:344-349.
16. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995;1:786-791.
17. Kufe D, Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003;2:326-329.
18. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311-4314.
19. Brurberg KG, Thuen M, Ruud EB, Rofstad EK. Fluctuations in pO2 in irradiated human melanoma xenografts. Radiat Res 2006;165:16-25.
20. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13:3395-3402.
21. Hou H, Khan N, Grinberg OY, Yu H, Grinberg SA, Lu S, Demidenko E, Steffen RP, Swartz HM. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res 2007;168: 218-225.
22. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
23. Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 2006;244:129-135.
24. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
25. Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 2007;67:9921-9928.
26. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563.
27. Fan X, Medved M, Karczmar GS, Yang C, Foxley S, Arkani S, Recant W, Zamora MA, Abe H, Newstead GM. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging 2007;25:593-603.
28. Fan X, Medved M, River JN, Zamora M, Corot C, Robert P, Bourrinet P, Lipton M, Culp RM, Karczmar GS. New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med 2004;51: 487-494.
29. Armitage P, Behrenbruch C, Brady M, Moore N. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal 2005;9:315-329.
30. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 1994;32:714-724.
31. Halpern HJ, Spencer DP, Vanpolen J, Bowman MK, Nelson AC, Dowey EM, Teicher BA. Imaging radio-frequency electron-spin-resonance spectrometer with high-resolution and sensitivity for in vivo measurements. Rev Sci Instrum 1989;60:1040-1050.
32. Halpern HJ, Yu C, Peric M, Barth E, Grdina DJ, Teicher BA. Oxymetry deep in tissues with low-frequency electron- paramagnetic-resonance. Proc Natl Acad S U S A 1994;91:13047-13051.
33. Haney CR, Parasca AD, Ichikawa K, Williams BB, Elas M, Pelizzari CA, Halpern HJ. Reduction of image artifacts in mice by bladder flushing with a novel double-lumen urethral catheter. Mol Imaging 2006;5:175-179.
34. Robinson BH, Mailer C, Reese AW. Linewidth analysis of spin labels in liquids. I. Theory and data analysis. J Magn Reson 1999;138:199-209.
35. Haney CR, Fan X, Parasca A, Karczmar GS, Halpern HJ, Pelizzari CA. Immobilization using dental material casts facilitates accurate serial and multimodality small animal imaging. Concepts Magn Reson Part B 2008;33B:138-144.
36. Grabstald H, Golbey R. Clinical experiences with thalidomide in patients with cancer. Clin Pharmacol Ther 1965;6:298-302.
37. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat Clin Pract Oncol 2006;3:682-692.
38. NIH Clinical Trials Database. 2008. Available at: clinicaltrials.gov/.